X0202 SCHEDULE 13G/A 0001425738 XXXXXXXX LIVE 7 Common Stock, $0.000001 par value 06/30/2026 0001404644 Neurogene Inc. 64135M105 535 W 24th Street, 5th Floor New York NY 10011 Rule 13d-1(b) Rule 13d-1(d) Redmile Group, LLC DE 0.00 1572202.00 0.00 1572202.00 1572202.00 N 9.9 IA OO The information in Item 4 relating to the shares of common stock, $0.000001 par value, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC and the calculation of the percent of such class of securities is incorporated by reference herein. Jeremy C. Green X0 0.00 1572202.00 0.00 1572202.00 1572202.00 N 9.9 HC IN The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the percent of such class of securities is incorporated by reference herein. Redmile Biopharma Investments I, L.P. DE 0.00 812033.00 0.00 812033.00 812033.00 N 5.1 PN The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Redmile Biopharma Investments I, L.P. and the calculation of the percent of such class of securities is incorporated by reference herein. Neurogene Inc. 535 W 24th Street, 5th Floor, New York, NY 10011 Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments I, L.P. Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments I, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments I, L.P.: Delaware Y Redmile Group, LLC - 1,572,202 (1) Jeremy C. Green - 1,572,202 (1) Redmile Biopharma Investments I, L.P. - 812,033 (2) Redmile Group, LLC - 9.9% (3) Jeremy C. Green - 9.9% (3) Redmile Biopharma Investments I, L.P. - 5.1% (3) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments I, L.P. - 0 Redmile Group, LLC - 1,572,202 (1) Jeremy C. Green - 1,572,202 (1) Redmile Biopharma Investments I, L.P. - 812,033 (2) Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments I, L.P. - 0 Redmile Group, LLC - 1,572,202 (1) Jeremy C. Green - 1,572,202 (1) Redmile Biopharma Investments I, L.P. - 812,033 (2) (1) Redmile's and Jeremy C. Green's beneficial ownership of the Issuer's Common Stock is comprised of (i) 1,412,199 shares of Common Stock and (ii) 160,003 shares of Common Stock issuable upon exercise of certain pre-funded warrants to purchase Common Stock (the "Warrants"). All of such shares of Common Stock and the Warrants are directly owned by certain investment vehicles, including Redmile Biopharma Investments I, L.P. ("RBI I"), for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as their investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any. (2) RBI I may be deemed to beneficially own (i) 652,030 shares of Common Stock, and (ii) 160,003 shares of Common Stock issuable upon exercise of the Warrants directly held by RBI I. (3) Percentage based on: (i) 15,801,901 shares of Common Stock outstanding as of May 8, 2026, as reported in the Form 10-Q for the quarterly period ended March 31, 2026 filed with the SEC on May 12, 2026; plus (ii) 160,003 shares of Common Stock issuable upon exercise of the Warrants. Y Y N See the response to Item 4. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Redmile Group, LLC /s/ Jeremy C. Green 08/14/2026 Jeremy C. Green /s/ Jeremy C. Green 08/14/2026 Redmile Biopharma Investments I, L.P. /s/ Jeremy C. Green 08/14/2026